Other · developed by VistaGen Therapeutics
Fasedienol is a nasal spray administered 20 minutes before anxiety-provoking situations. It is studied for social anxiety disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06358651 | Phase 3 | Social Anxiety Disorder | Active not recruiting | VTGN |
| NCT05030350 | Phase 3 | Social Anxiety Disorder | Terminated | VTGN |
| NCT05011396 | Phase 3 | Social Anxiety Disorder | Terminated | VTGN |
| NCT06809179 | Phase 2 | Social Anxiety Disorder | Recruiting | VTGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Social Anxiety Disorder
Updated Oct 3, 2026. Something wrong or missing? Report it on the VTGN page.
See VTGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VTGN catalysts and pipeline →